These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32497335)

  • 1. Post Transplant Lymphoproliferative Disorder risk factors in children: Analysis of a 23-year single-institutional experience.
    Bosse RC; Franke AJ; Paul Skelton W; Woody LE; Bishnoi R; Wang Y; Bhaduri-McIntosh S; Rajderkar D; Shih R; Dang NH; Slayton WB
    Pediatr Transplant; 2020 Aug; 24(5):e13747. PubMed ID: 32497335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction regimens and post-transplantation lymphoproliferative disorder after pediatric intestinal transplantation: Single-center experience.
    Devine K; Ranganathan S; Mazariegos G; Bond G; Soltys K; Ganoza A; Sun Q; Sindhi R
    Pediatr Transplant; 2020 Aug; 24(5):e13723. PubMed ID: 32424963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics, risks, and outcomes of post-transplant lymphoproliferative disease >3 years after pediatric heart transplant: A multicenter analysis.
    West SC; Friedland-Little JM; Schowengerdt KO; Naftel DC; Pruitt Freeze E; Smith KS; Urschel S; Michaels MG; Kirklin JK; Feingold B
    Clin Transplant; 2019 May; 33(5):e13521. PubMed ID: 30861200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-transplant lymphoproliferative disorder following pediatric heart transplantation.
    Mendoza F; Kunitake H; Laks H; Odim J
    Pediatr Transplant; 2006 Feb; 10(1):60-6. PubMed ID: 16499589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter survey on post-transplant lymphoproliferative disorders in pediatric heart transplant recipients: A case for development of consensus guidelines for screening, surveillance, and treatment?
    Weisert M; Harake D; Hede S; Russell M; Alejos J; Menteer J
    Pediatr Transplant; 2020 Aug; 24(5):e13730. PubMed ID: 32416037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorder.
    Rouphael B; Lankireddy S; Lazaryan A; Kukla A; Ibrahim HN; Matas AJ; Issa N
    Clin Transplant; 2016 Jan; 30(1):60-5. PubMed ID: 26497471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying predictive factors for posttransplant lymphoproliferative disease in pediatric solid organ transplant recipients with Epstein-Barr virus viremia.
    Weintraub L; Weiner C; Miloh T; Tomaino J; Joashi U; Benchimol C; Strauchen J; Roth M; Wistinghausen B
    J Pediatr Hematol Oncol; 2014 Nov; 36(8):e481-6. PubMed ID: 24878618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-transplantation lymphoproliferative disease in pediatric liver recipients in Taiwan.
    Hsu CT; Chang MH; Ho MC; Chang HH; Lu MY; Jou ST; Ni YH; Chen HL; Hsu HY; Wu JF
    J Formos Med Assoc; 2019 Nov; 118(11):1537-1545. PubMed ID: 30630698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
    Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
    Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of immunosuppression for post-transplant lymphoproliferative disorder (PTLD): a single-center experience of allograft survival outcomes.
    Pan K; Franke AJ; Skelton WP; Bishnoi R; Shah C; Dang NH; Alquadan K
    Leuk Lymphoma; 2021 May; 62(5):1123-1128. PubMed ID: 33327817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.
    Maecker B; Jack T; Zimmermann M; Abdul-Khaliq H; Burdelski M; Fuchs A; Hoyer P; Koepf S; Kraemer U; Laube GF; Müller-Wiefel DE; Netz H; Pohl M; Toenshoff B; Wagner HJ; Wallot M; Welte K; Melter M; Offner G; Klein C
    J Clin Oncol; 2007 Nov; 25(31):4902-8. PubMed ID: 17971586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posttransplant lymphoproliferative disorder in pediatric patients: Survival rates according to primary sites of occurrence and a proposed clinical categorization.
    L'Huillier AG; Dipchand AI; Ng VL; Hebert D; Avitzur Y; Solomon M; Ngan BY; Stephens D; Punnett AS; Barton M; Allen UD
    Am J Transplant; 2019 Oct; 19(10):2764-2774. PubMed ID: 30884098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation.
    Orjuela MA; Alobeid B; Liu X; Siebert AL; Kott ER; Addonizio LJ; Morris E; Garvin JH; Lobritto SJ; Cairo MS
    Br J Haematol; 2011 Mar; 152(6):733-42. PubMed ID: 21275950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.
    Kogan-Liberman D; Burroughs M; Emre S; Moscona A; Shneider BL
    J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):445-9. PubMed ID: 11698761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for adenotonsillar hypertrophy in children following solid organ transplantation.
    Shapiro NL; Strocker AM; Bhattacharyya N
    Int J Pediatr Otorhinolaryngol; 2003 Feb; 67(2):151-5. PubMed ID: 12623151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
    Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB
    Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human leukocyte antigen type and posttransplant lymphoproliferative disorder.
    Lustberg ME; Pelletier RP; Porcu P; Martin SI; Quinion CD; Geyer SM; Caligiuri MA; Baiocchi RA
    Transplantation; 2015 Jun; 99(6):1220-5. PubMed ID: 25427163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.
    Manlhiot C; Pollock-Barziv SM; Holmes C; Weitzman S; Allen U; Clarizia NA; Ngan BY; McCrindle BW; Dipchand AI
    J Heart Lung Transplant; 2010 Jun; 29(6):648-57. PubMed ID: 20304682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.